loose...does it kind of depend on the company that we partner with or buys the indication? For example, Lilly is the maker of cisplatin and could essentially charge the conservative value you mention for B-OM which would potentially help the chemo treatments to keep going; the patient would benefit and so would Lilly. However, another BP who needs to focus on increasing revenue may not be willing to charge less. If they conservatively charged half of the cost of SOM (say $10K of the $18-25K) the numbers jump dramatically. It will be interesting to see how this all plays out....good topic.